{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:58:06Z","timestamp":1778540286923,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Dalbavancin is a novel lipoglycopeptide with potent activity against several gram-positive pathogens, an excellent safety profile and a long elimination half-life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this case series observed at the University Hospital of Vienna between 2015 and 2017, all adult patients with gram-positive infections who received at least one dosage of dalbavancin were screened (<jats:italic>n<\/jats:italic>\u2009=\u2009118). A total of 72 patients were included in the final analysis. The number of included patients stratified by the source of infection was: skin and soft tissue infection (SSTI) (<jats:italic>n<\/jats:italic>\u2009=\u200926), osteomyelitis (<jats:italic>n<\/jats:italic>\u2009=\u200920), spondylodiscitis (<jats:italic>n<\/jats:italic>\u2009=\u200914), acute septic arthritis (<jats:italic>n<\/jats:italic>\u2009=\u20094) and prosthetic joint infection (<jats:italic>n<\/jats:italic>\u2009=\u20098).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In 46 patients (64%), clinical cure was detected at the end of dalbavancin therapy without additional antibiotic therapy. Of the 26 patients who received additional antibiotic therapy other than dalbavancin, 15 patients (21%) showed no clinical improvement under dalbavancin therapy, four patients (5%) had side effects (nausea <jats:italic>n<\/jats:italic>\u2009=\u20091, exanthema <jats:italic>n<\/jats:italic>\u2009=\u20092, hyperglycemia <jats:italic>n<\/jats:italic>\u2009=\u20091), and in seven patients (10%) clinical improvement under dalbavancin therapy was detected but antibiotic therapy was de-escalated to an oral drug.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We demonstrated high clinical effectiveness of dalbavancin for acute gram-positive infections primarily acute SSTI, acute septic arthritis, acute osteomyelitis and spondylodiscitis. In patients with biofilm-associated infection (chronic infection or joint prosthesis), source control was absolutely necessary for treatment success.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s15010-019-01354-x","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T19:10:41Z","timestamp":1568401841000},"page":"1013-1020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8241-8317","authenticated-orcid":false,"given":"Selma","family":"Tobudic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Forstner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Burgmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heimo","family":"Lagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludwig","family":"Traby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias G.","family":"Vossen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Thalhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"1354_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","volume":"11","author":"F Menichetti","year":"2005","unstructured":"Menichetti F. Current and emerging serious gram-positive infections. Clin Microbiol Infect. 2005;11:22\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"1354_CR2","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S0163-4453(09)60003-7","volume":"59","author":"N Woodford","year":"2009","unstructured":"Woodford N, Livermore DM. Infections caused by gram-positive bacteria: a review of the global challenge. J Infect. 2009;59:S4\u201316.","journal-title":"J Infect"},{"key":"1354_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/cid\/civ982","volume":"62","author":"MW Dunne","year":"2016","unstructured":"Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62:545\u201351.","journal-title":"Clin Infect Dis"},{"key":"1354_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ijantimicag.2017.05.006","volume":"50","author":"MZ David","year":"2017","unstructured":"David MZ, Dryden M, Gottlieb T, Tattevin P, Gould IM. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive pathogens: the shock of the new. Int J Antimicrob Agents. 2017;50:303\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"1354_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2015.01.017","volume":"82","author":"RN Jones","year":"2015","unstructured":"Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE. Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. Diagn Microbiol Infect Dis. 2015;82:73\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1354_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.diagmicrobio.2013.01.003","volume":"76","author":"RN Jones","year":"2013","unstructured":"Jones RN, Flamm RK, Sader HS. Surveillance of dalbavancin potency and spectrum in the United States (2012). Diagn Microbiol Infect Dis. 2013;76:122\u20133.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1354_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of vienna. Clin Infect Dis. 2018;67:795\u20138.","journal-title":"Clin Infect Dis"},{"key":"1354_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodriguez-Gonzalez C, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51:571\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"1354_CR9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","volume":"75","author":"RN Jones","year":"2013","unstructured":"Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013;75:304\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1354_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jac\/dkv303","volume":"71","author":"RE Mendes","year":"2016","unstructured":"Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN. Update on dalbavancin activity tested against gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011\u201313). J Antimicrob Chemother. 2016;71:276\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"1354_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1128\/AAC.01453-08","volume":"53","author":"DJ Biedenbach","year":"2009","unstructured":"Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53:1260\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"1354_CR12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","volume":"48","author":"A Leighton","year":"2004","unstructured":"Leighton A, Gottlieb AB, Dorr MB, Jabes D, Mosconi G, VanSaders C, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004;48:940\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"ii25","DOI":"10.1093\/jac\/dki008","volume":"55","author":"MB Dorr","year":"2005","unstructured":"Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005;55:ii25\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"1354_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/0091270008330162","volume":"49","author":"T Marbury","year":"2009","unstructured":"Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol. 2009;49:465\u201376.","journal-title":"J Clin Pharmacol"},{"key":"1354_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1177\/0091270008321273","volume":"48","author":"JA Dowell","year":"2008","unstructured":"Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic. J Clin Pharmacol. 2008;48:1063\u20138.","journal-title":"J Clin Pharmacol"},{"key":"1354_CR16","doi-asserted-by":"publisher","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","volume":"6","author":"U Rappo","year":"2019","unstructured":"Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019;6:ofy331.","journal-title":"Open Forum Infect Dis"},{"key":"1354_CR17","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1128\/AAC.04550-14","volume":"59","author":"MW Dunne","year":"2015","unstructured":"Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother. 2015;59:1849\u201355.","journal-title":"Antimicrob Agents Chemother"},{"key":"1354_CR18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169\u201379.","journal-title":"N Engl J Med"},{"key":"1354_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","volume":"81","author":"S Wunsch","year":"2019","unstructured":"Wunsch S, Krause R, Valentin T, Prattes J, Janata O, Lenger A, et al. Multicenter clinical experience of real life dalbavancin use in gram-positive infections. Int J Infect Dis. 2019;81:210\u20134.","journal-title":"Int J Infect Dis"},{"key":"1354_CR20","unstructured":"Jandourek Alena SV, Schvenko O, Rappo U, Gonzalez P, Puttagunta S, Dunne M, Miceli R, Kovacevic M, De Bock G. Dalbavancin for the treatment of osteomyelitis in adult patients. Eur Congr Clin Microbiol Infect Dis. 2017."},{"issue":"5","key":"1354_CR21","doi-asserted-by":"publisher","first-page":"e02280-18","DOI":"10.1128\/AAC.02280-18","volume":"63","author":"L Morata","year":"2019","unstructured":"Morata L, Cobo J, Fernandez-Sampedro M, Vasco PG, Ruano E, Lora-Tamayo J, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019;63(5):e02280-18. \nhttps:\/\/doi.org\/10.1128\/AAC.02280-18\n\n.","journal-title":"Antimicrob Agents Chemother"},{"key":"1354_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/14787210.2018.1417036","volume":"16","author":"JL Del Pozo","year":"2018","unstructured":"Del Pozo JL. Biofilm-related disease. Expert Rev Anti Infect Ther. 2018;16:51\u201365.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1354_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-016-2845-z","volume":"36","author":"D Knafl","year":"2017","unstructured":"Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F. Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 2017;36:677\u201380.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1354_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.diagmicrobio.2017.09.015","volume":"90","author":"K Neudorfer","year":"2018","unstructured":"Neudorfer K, Schmidt-Malan SM, Patel R. Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci. Diagn Microbiol Infect Dis. 2018;90:58\u201363.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1354_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(14)61233-2","volume":"385","author":"L Bernard","year":"2015","unstructured":"Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, et al. Antibiotic treatment for 6\u00a0weeks versus 12\u00a0weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015;385:875\u201382.","journal-title":"Lancet"},{"key":"1354_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa1710926","volume":"380","author":"HK Li","year":"2019","unstructured":"Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380:425\u201336.","journal-title":"N Engl J Med"},{"key":"1354_CR27","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMra040181","volume":"351","author":"W Zimmerli","year":"2004","unstructured":"Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351:1645\u201354.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s15010-019-01372-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T00:00:00Z","timestamp":1574035200000}}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-019-01354-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-019-01354-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-019-01354-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T18:14:07Z","timestamp":1600280047000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-019-01354-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1007\/s15010-019-01354-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s15010-019-01372-9","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"assertion":[{"value":"18 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake. The presentation of Fig.\u00a01 was incorrect. The corrected figure is given below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake. The presentation of Fig.\ufffd\ufffd1 was incorrect. The corrected figure is given below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}